The DOI matches its Crossref record; 115 of the 115 references it cites were found in a registry or an index.
Mechanisms of Multidrug Resistance in Cancer Chemotherapy
Open accessAbstract
Cancer is one of the main causes of death worldwide. Despite the significant development of methods of cancer healing during the past decades, chemotherapy still remains the main method for cancer treatment. Depending on the mechanism of action, commonly used chemotherapeutic agents can be divided into several classes (antimetabolites, alkylating agents, mitotic spindle inhibitors, topoisomerase inhibitors, and others). Multidrug resistance (MDR) is responsible for over 90% of deaths in cancer patients receiving traditional chemotherapeutics or novel targeted drugs. The mechanisms of MDR include elevated metabolism of xenobiotics, enhanced efflux of drugs, growth factors, increased DNA repair capacity, and genetic factors (gene mutations, amplifications, and epigenetic alterations). Rapidly increasing numbers of biomedical studies are focused on designing chemotherapeutics that are able to evade or reverse MDR. The aim of this review is not only to demonstrate the latest data on the mechanisms of cellular resistance to anticancer agents currently used in clinical treatment but also to present the mechanisms of action of novel potential antitumor drugs which have been designed to overcome these resistance mechanisms. Better understanding of the mechanisms of MDR and targets of novel chemotherapy agents should provide guidance for future research concerning new effective strategies in cancer treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Chen, L., Li, X., Cheng, M., Wang, S., Zheng, Q., & Liu, Q. (2018) · RSC Advances · doi:10.1039/c8ra09506j · Cited by 11
RetractedGlobal Burden of Disease Cancer Collaboration, Fitzmaurice, C., Allen, C., Barber, R. M., Barregard, L., Bhutta, Z. A., Brenner, H., Dicker, D. J., Chimed-Orchir, O., Dandona, R., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.5688 · Cited by 6,215
The Different Mechanisms of Cancer Drug Resistance: A Brief Review
Mansoori, B., Mohammadi, A., Davudian, S., Shirjang, S., & Baradaran, B. (2017) · Advanced Pharmaceutical Bulletin · doi:10.15171/apb.2017.041 · Cited by 1,883
DNA repair pathways as targets for cancer therapy
Helleday, T., Petermann, E., Lundin, C., Hodgson, B., & Sharma, R. A. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2342 · Cited by 1,666
Fitzmaurice, C., & Global Burden of Disease Cancer Collaboration (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.1568 · Cited by 1,646
Glutathione metabolism in cancer progression and treatment resistance
Bansal, A., & Simon, M. C. (2018) · Journal of Cell Biology · doi:10.1083/jcb.201804161 · Cited by 1,233
Drug resistance and combating drug resistance in cancer
Wang, X., Zhang, H., & Chen, X. (2019) · Cancer Drug Resistance · doi:10.20517/cdr.2019.10 · Cited by 1,085
The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin
Greiner, B., Eichelbaum, M., Fritz, P., Kreichgauer, H.-P., von Richter, O., Zundler, J., & Kroemer, H. K. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6663 · Cited by 917
Multi-drug resistance in cancer chemotherapeutics: Mechanisms and lab approaches
Wu, Q., Yang, Z., Nie, Y., Shi, Y., & Fan, D. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.03.013 · Cited by 776
Mutant p53 as a guardian of the cancer cell
Mantovani, F., Collavin, L., & Del Sal, G. (2019) · Cell Death & Differentiation · doi:10.1038/s41418-018-0246-9 · Cited by 775
Research works printed but not linked: 12
- Marchi, 2012, Safety and efficacy of pralatrexate in the treatment of patients with relapsed or refractory peripheral T-cell lymphoma, Ther. Adv. Hematol., 3, 227, 10.1177/2040620712445330 · doi:10.1177/2040620712445330
- Le, T., Bhushan, V., Sochat, M., and Chavda, Y. (2017). First Aid for the USMLE Step 1, McGraw-Hill Education. [1st ed.].
- Mesci, 2019, The effect of ATP-binding cassette (ABC) transporters in human cancers, Int. J. Sci. Lett., 1, 1, 10.38058/ijsl.594000 · doi:10.38058/ijsl.594000
- Zu, 2014, Effects of P-glycoprotein and its inhibitors on apoptosis in K562 cells, Molecules, 19, 13061, 10.3390/molecules190913061 · doi:10.3390/molecules190913061
- Satake, 2015, Human ABCB1 confers cells resistance to cytotoxic guanidine alkaloids from Pterogyne nitens, Biomed. Mater. Eng., 25, 249
- Galski, 2013, P-glycoprotein-dependent resistance of cancer cells toward the extrinsic TRAIL apoptosis signaling pathway, Biochem Pharmacol., 86, 584, 10.1016/j.bcp.2013.06.004 · DOI
- Zhou, 2017, Tomentodione M sensitizes multidrug resistant cancer cells by decreasing P-glycoprotein via inhibition of p38 MAPK signaling, Oncotarget, 8, 101965, 10.18632/oncotarget.21949 · DOI
- Greenfield, G., McMullan, R., Robson, N., McGimpsey, J., Catherwood, M., and McMullin, M.F. (2019). Response to Imatinib therapy is inferior for e13a2 BCR-ABL1 transcript type in comparison to e14a2 transcript type in chronic myeloid leukaemia. BMC Hematol., 19. · doi:10.1186/s12878-019-0139-2
- Lin, 2015, Upregulation of microRNA-224 sensitizes human cervical cells SiHa to paclitaxel, Eur. J. Gynaecol. Oncol., 36, 432
- Chapman, 2015, Catechols and 3-hydroxypyridones as inhibitors of the DNA repair complex ERCC1-XPF, Bioorg. Med. Chem. Lett., 25, 4097, 10.1016/j.bmcl.2015.08.031 · doi:10.1016/j.bmcl.2015.08.031
- Wu, 2010, Phase II study of darinaparsin in patients with advanced hepatocellular carcinoma, Invest. New Drugs, 28, 670, 10.1007/s10637-009-9286-9 · doi:10.1007/s10637-009-9286-9
- Demir, 2018, Evaluation of chalcones as inhibitors of glutathione S-transferase, J. Biochem. Mol. Toxicol., 32, e22047, 10.1002/jbt.22047 · doi:10.1002/jbt.22047
Cited by
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Zhong, L., Li, Y., Xiong, L., Wang, W., Wu, M., Yuan, T., Yang, W., Tian, C., Miao, Z., Wang, T., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00572-w · Cited by 1,696
PI3K/AKT pathway as a key link modulates the multidrug resistance of cancers
Liu, R., Chen, Y., Liu, G., Li, C., Song, Y., Cao, Z., Li, W., Hu, J., Lu, C., & Liu, Y. (2020) · Cell Death & Disease · doi:10.1038/s41419-020-02998-6 · Cited by 923
Regulated cell death (RCD) in cancer: key pathways and targeted therapies
Peng, F., Liao, M., Qin, R., Zhu, S., Peng, C., Fu, L., Chen, Y., & Han, B. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01110-y · Cited by 832
Doxorubicin—An Agent with Multiple Mechanisms of Anticancer Activity
Kciuk, M., Gielecińska, A., Mujwar, S., Kołat, D., Kałuzińska-Kołat, Ż., Celik, I., & Kontek, R. (2023) · Cells · doi:10.3390/cells12040659 · Cited by 810
Self-citationThe Hippo signalling pathway and its implications in human health and diseases
Fu, M., Hu, Y., Lan, T., Guan, K.-L., Luo, T., & Luo, M. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01191-9 · Cited by 742
Theranostic Fluorescent Probes
Sharma, A., Verwilst, P., Li, M., Ma, D., Singh, N., Yoo, J., Kim, Y., Yang, Y., Zhu, J.-H., Huang, H., et al. (2024) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00778 · Cited by 499
Apoptosis Deregulation and the Development of Cancer Multi-Drug Resistance
Neophytou, C. M., Trougakos, I. P., Erin, N., & Papageorgis, P. (2021) · Cancers · doi:10.3390/cancers13174363 · Cited by 371
Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer
Labrie, M., Brugge, J. S., Mills, G. B., & Zervantonakis, I. K. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00454-5 · Cited by 369
Overcoming cancer chemotherapy resistance by the induction of ferroptosis
Wang, Y., Wu, X., Ren, Z., Li, Y., Zou, W., Chen, J., & Wang, H. (2023) · Drug Resistance Updates · doi:10.1016/j.drup.2022.100916 · Cited by 361
Understanding and targeting resistance mechanisms in cancer
Lei, Z., Tian, Q., Teng, Q., Wurpel, J. N. D., Zeng, L., Pan, Y., & Chen, Z. (2023) · MedComm · doi:10.1002/mco2.265 · Cited by 347
Emerging Therapeutic Strategies to Overcome Drug Resistance in Cancer Cells
Garg, P., Malhotra, J., Kulkarni, P., Horne, D., Salgia, R., & Singhal, S. S. (2024) · Cancers · doi:10.3390/cancers16132478 · Cited by 339
“…significantly to the failure of chemotherapy [2,10]. expressed in many types of cancer, contributing significantly to the failure of chemotherapy [2,10] Multidrug Multidrug resistance proteins (MRPs) are another important group of efflux transporters. proteins (MRPs) are another important group of…”
BackgroundDuan, C., Yu, M., Xu, J., Li, B.-Y., Zhao, Y., & Kankala, R. K. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114643 · Cited by 335
Battling Chemoresistance in Cancer: Root Causes and Strategies to Uproot Them
Ramos, A., Sadeghi, S., & Tabatabaeian, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179451 · Cited by 289
Li, B., Shao, H., Gao, L., Li, H., Sheng, H., & Zhu, L. (2022) · Drug Delivery · doi:10.1080/10717544.2022.2094498 · Cited by 289
The Promise of Nanotechnology in Personalized Medicine
Alghamdi, M. A., Fallica, A. N., Virzì, N., Kesharwani, P., Pittalà, V., & Greish, K. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12050673 · Cited by 284
Potential mechanisms of quercetin in cancer prevention: focus on cellular and molecular targets
Asgharian, P., Tazekand, A. P., Hosseini, K., Forouhandeh, H., Ghasemnejad, T., Ranjbar, M., Hasan, M., Kumar, M., Beirami, S. M., Tarhriz, V., et al. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02677-w · Cited by 274
Irinotecan—Still an Important Player in Cancer Chemotherapy: A Comprehensive Overview
Kciuk, M., Marciniak, B., & Kontek, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21144919 · Cited by 266
Self-citationTherapeutic strategies to overcome taxane resistance in cancer
Das, T., Anand, U., Pandey, S. K., Ashby, C. R., Assaraf, Y. G., Chen, Z.-S., & Dey, A. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100754 · Cited by 253
Hanssen, K. M., Haber, M., & Fletcher, J. I. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100795 · Cited by 102
Yee Kuen, C., & Masarudin, M. J. (2022) · Molecules · doi:10.3390/molecules27020473 · Cited by 78
Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer
Haynes, J., & Manogaran, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051988 · Cited by 82
“It is an alkylating agent that damages DNA and inhibits DNA synthesis [30,31].”
Recent advances in targeted drug delivery systems for resistant colorectal cancer
Sharifi-Azad, M., Fathi, M., Cho, W. C., Barzegari, A., Dadashi, H., Dadashpour, M., & Jahanban-Esfahlan, R. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02605-y · Cited by 65
Beygi, M., Oroojalian, F., Hosseini, S. S., Mokhtarzadeh, A., Kesharwani, P., & Sahebkar, A. (2023) · Progress in Materials Science · doi:10.1016/j.pmatsci.2023.101209 · Cited by 32
RetractedKarthika, C., Sureshkumar, R., Zehravi, M., Akter, R., Ali, F., Ramproshad, S., Mondal, B., Kundu, M. K., Dey, A., Rahman, M. H., et al. (2022) · Life · doi:10.3390/life12060811 · Cited by 30
“P-gp is the main reason for MDR in cancer cells [76].”
BackgroundEcdysteroid derivatives that reverse P-glycoprotein-mediated drug resistance
Bortolozzi, R., Luraghi, A., Mattiuzzo, E., Sacchetti, A., Silvani, A., & Viola, G. (2020) · Journal of Natural Products · doi:10.1021/acs.jnatprod.0c00334 · Cited by 21
Wang, Y., Tu, M.-J., & Yu, A.-M. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1423416 · Cited by 21
Metabolic reprogramming: The driving force behind cancer drug resistance
El-Sehrawy, A. A. M. A., Hsu, C.-Y., Alkhathami, A. G., Chandra, M., Basunduwah, T. S., Malathi, H., Senapati, J. N., Gautam, A., Kadhem, M., & Yasin, H. A. (2025) · Seminars in Oncology · doi:10.1016/j.seminoncol.2025.152392 · Cited by 11
pH-Responsive Natural Polymers as Versatile Carriers for Drug Delivery in Breast Cancer: A Review
Velapure, P. D., Chakote, S. R., Kansal, D., Barooah, A., Pawde, D. M., & Bobade, C. D. (2026) · Biomedical Materials & Devices · doi:10.1007/s44174-025-00427-w · Cited by 5
Metadata
- Authors
- Bukowski, K., Kciuk, M., & Kontek, R.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2020-05-02
- Volume
- 21
- Issue
- 9
- Pages
- 3233
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W3021909056
- Cited by
- 1,757
- References
- 115
- FWCI
- 66.81
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.